Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics with or without loperamide to prevent pyrotinib-induced diarrhea in HER2-positive breast cancer
ChiCTR2100051163Phase 4Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of loperamide in breast cancer (3 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Incidence of grade 3 or higher diarrhea. Started Aug 2021; status: recruiting.
02
Drugs
loperamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100051163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051163.